FDA
-
-
-
-
-
-
-
Actuate Therapeutics gets FDA clearance for oral elraglusib trial
-
-
-
-
-
-
-
Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers
-
-
-
-
-
-
-
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metast
-
-
-
-
-
-
-
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Ca
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Actuate Therapeutics (ACTU)
-
-
-
-
-
-
-
Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
-
-
-
-
-
-
-
Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025
-
329,070 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

